Bristol's Melanoma Drug Could Make the Stock a Buy

clipped from www.minyanville.com The silent one is a Pfizer (PFE) drug called crazotinib (formerly known under the sexy name of PF-02341066), which shows amazing efficacy in a targeted population of non-small cell lung cancer (NSCLC) patients. Crazotinib Phase II data are so good, the expert reviewer of the data presentation called for its immediate approval -- before it completes Phase III trials. The loud one is ipilimumab, or “ipi” for short. This drug was developed by Medarex, which was acquired by Bristol-Myers Squibb (BMY). Bristol is claiming ipi demonstrated the first survival advantage in Stage IV metastatic melanoma ever seen. It's clearly the most hyped drug at this conference. So does it live up to the hype?